A consortium of investors, including Pappas Capital, NYBC Ventures, Hatteras Venture Partners, Sanofi Ventures, JDRF T1D Fund and Genesys Capital, led a $24m round in Veralox. “VLX-1005 has great promise to revolutionize the treatment of HIT and other immune-mediated diseases. I am thrilled to join the board at such an exciting time, and to be working with a leader of Jonathan’s caliber to move into later stages of clinical development," Peter Young, Pappas Capital Partner.